Versant Venture Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $8.23M | Hold |
148,831
| – | – | 7.55% | 6 |
|
|
2026
Q2 | $8.12M | Hold |
148,831
| – | – | 4.99% | 6 |
|
|
2026
Q1 | $7.08M | Hold |
148,831
| – | – | 5.01% | 6 |
|
|
2025
Q4 | $7.8M | Hold |
148,831
| – | – | 5.17% | 4 |
|
|
2025
Q3 | $9.6M | Sell |
148,831
-349,727
| -70% | -$20.1M | 4.54% | 4 |
|
|
2025
Q2 | $24.2M | Hold |
498,558
| – | – | 29.52% | 2 |
|
|
2025
Q1 | $17M | Hold |
498,558
| – | – | 28.18% | 2 |
|
|
2024
Q4 | $19.6M | Hold |
498,558
| – | – | 22.62% | 2 |
|
|
2024
Q3 | $23.4M | Hold |
498,558
| – | – | 36.84% | 1 |
|
|
2024
Q2 | $26.9M | Hold |
498,558
| – | – | 34.84% | 1 |
|
|
2024
Q1 | $34M | Hold |
498,558
| – | – | 32.95% | 1 |
|
|
2023
Q4 | $31.2M | Hold |
498,558
| – | – | 8.03% | 2 |
|
|
2023
Q3 | $22.6M | Hold |
498,558
| – | – | 12.03% | 3 |
|
|
2023
Q2 | $28M | Hold |
498,558
| – | – | 33.2% | 2 |
|
|
2023
Q1 | $22.5M | Hold |
498,558
| – | – | 47.01% | 1 |
|
|
2022
Q4 | $20.3M | Hold |
498,558
| – | – | 41.93% | 1 |
|
|
2022
Q3 | $32.6M | Hold |
498,558
| – | – | 55.55% | 1 |
|
|
2022
Q2 | $30.3M | Hold |
498,558
| – | – | 46.45% | 1 |
|
|
2022
Q1 | $31.3M | Hold |
498,558
| – | – | 31.24% | 1 |
|
|
2021
Q4 | $37.8M | Hold |
498,558
| – | – | 20.21% | 2 |
|
|
2021
Q3 | $55.8M | Sell |
498,558
-10,000
| -2% | -$1.26M | 23.11% | 1 |
|
|
2021
Q2 | $82.3M | Sell |
508,558
-1,046,402
| -67% | -$127M | 27.28% | 1 |
|
|
2021
Q1 | $189M | Sell |
1,554,960
-1,485,502
| -49% | -$224M | 36.92% | 1 |
|
|
2020
Q4 | $466M | Sell |
3,040,462
-591,194
| -16% | -$69.9M | 48.34% | 1 |
|
|
2020
Q3 | $304M | Sell |
3,631,656
-551,408
| -13% | -$48.9M | 55.59% | 1 |
|
|
2020
Q2 | $307M | Sell |
4,183,064
-22,551
| -0.5% | -$1.32M | 44.16% | 1 |
|
|
2020
Q1 | $177M | Hold |
4,205,615
| – | – | 48.6% | 1 |
|
|
2019
Q4 | $256M | Sell |
4,205,615
-28,255
| -0.7% | -$1.54M | 77.19% | 1 |
|
|
2019
Q3 | $174M | Sell |
4,233,870
-15,018
| -0.4% | -$718K | 67.15% | 1 |
|
|
2019
Q2 | $200M | Hold |
4,248,888
| – | – | 58.31% | 1 |
|
|
2019
Q1 | $152M | Buy |
4,248,888
+640,014
| +18% | +$22.1M | 50% | 1 |
|
|
2018
Q4 | $103M | Hold |
3,608,874
| – | – | 51.04% | 1 |
|
|
2018
Q3 | $160M | Hold |
3,608,874
| – | – | 54.44% | 1 |
|
|
2018
Q2 | $212M | Sell |
3,608,874
-997,368
| -22% | -$56.8M | 66.16% | 1 |
|
|
2018
Q1 | $211M | Buy |
+4,606,242
| New | +$190M | 67.34% | 1 |
|
Other funds holding CRSP
Versant Venture Management's CRSP Position: Q3 2026 in Review
Versant Venture Management held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 148,831 shares worth $8.23M. The position accounts for 7.55% of the portfolio, ranked #6.
Versant Venture Management first reported a position in CRSP in Q1 2018 and has held it in 35 quarters since. The position peaked at $466M in Q4 2020. 504 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Versant Venture Management held 148,831 shares of CRISPR Therapeutics worth $8.23M as of Q3 2026.
- Versant Venture Management left its CRISPR Therapeutics share count unchanged in Q3 2026.
- CRISPR Therapeutics made up 7.55% of Versant Venture Management's portfolio in Q3 2026, its #6 holding.
- Versant Venture Management first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 35 quarters since.
- Versant Venture Management's CRISPR Therapeutics position peaked at $466M in Q4 2020.
- 504 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Versant Venture Management's 13F filing for Q3 2026, filed 13 Nov 2026.